Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:59 PM EDT
690.44
+4.42 (+0.64%)
Products, Regulatory, Other Pre-Announcement

Sanofi: Dupixent peak sales ambition raised to more than €13 billion

Published: 03/29/2022 04:41 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Reg-press Release: Sanofi Continues on Path to Industry Leadership in Immunology With Dupixent® (dupilumab) As Key Driver.
Dupixent Peak Sales Ambition Raised to More Than €13 Billion.
Chronic Obstructive Pulmonary Disease 2023 Pivotal Readouts Provide Potential for Additional Dupixent Sales Ambition Upgrade.
13 Potential New Medicines Currently in the Clinic to Treat Chronic Inflammatory Diseases, With 17 Readouts Expected by the End of 2024.